SearchSearch results for: “”

Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.

Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.

Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.

Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.

Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b

Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.

Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.

Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.

Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.

Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.

Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.